Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News on Pharma

Syntex: How To Find & Own America's Greatest Opportunities

Syntex made a move of 450% in about six months and this drug stock was one of my best winners.

Investors Business Daily

All the health conditions weight-loss drugs are being used and tested for

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some success

The Independent UK

Why Drugmaker Teva Pharmaceutical Narrowed Full-Year Guidance After Beating Q2 Earnings

Teva stock is trading below key levels.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

UnitedHealth Stock Drags on Dow: Stock Market Today

Corporate earnings have dominated Wall Street's attention this week, but that changes on Wednesday.

Kiplinger

Ministers take note: now is the moment to fight to keep AstraZeneca’s listing in London

One hopes cogs are turning in Westminster after Pascal Soriot’s affectionate talk of US at pharmaceutical giant’s half-year results

The Guardian - UK

US health officials crack down on kratom-related products after complaints from supplement industry

U.S. health officials are cracking down on an opioid-like ingredient being added to drinks, supplements and other products

The Independent UK

Novo Nordisk Cuts Earning Forecasts Again, Names New CEO

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, on Tuesday lowered its earning forecasts again as it unveiled a new chief executive to tackle "recent market challenges".

International Business Times

Read news from The Economist, FT, and more,
with one subscription

AstraZeneca chief executive hails ‘vital importance of US’ as Trump tariffs loom

Pascal Soriot refuses to be drawn, however, on reports AZ could move its main stock market listing across the Atlantic

The Guardian - UK

Merck Stock Falls After Layoff Announcement, Gardasil Sales Drop

Merck stock fell early Tuesday after Q2 results. The Dow Jones drugmaker plans for job cuts as part of restructuring initiative.

Investors Business Daily

Trump’s 15% tariff on medicines will harm patients, say EU drugmakers

Trade group says levy will reduce access, disrupt supply chains and cut R&D

The Guardian - UK

$Garmin-style energy tracking just arrived on a wearable that costs a fraction of a new Fenix$

Garmin-style energy tracking just arrived on a wearable that costs a fraction of a new Fenix

New BioCharge Energy feature brings real-time recovery insights to Amazfit’s affordable Helio Strap

Sarepta will resume gene therapy shipments after FDA review of recent patient death

Shares of drugmaker Sarepta Therapeutics surged in afterhours trading Monday after the company said it would resume shipping its gene therapy

The Independent UK

Ireland's 'Economic Miracle' At Risk From Tariffs

The deal between the United States and the European Union may have averted a transatlantic trade war, but worries persist in Ireland where crucial sectors are dependent on US multinationals.

International Business Times

Weight-loss jab Wegovy sees another prescription boost after ban on copycats

Novo CEO ousted in May, in place until successor named

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Sarepta Therapeutics' Brutal Week Continues With Bad News Out Of Europe

Sarepta Therapeutics' brutal week continued Friday after European officials rejected the company's controversial gene therapy, Elevidys.

Investors Business Daily

The Hits Keep Coming For Sarepta. Why Its Latest Setback Creates A 'Dangerous Precedent.'

Sarepta stock plunged again Thursday on a report the FDA will require additional clinical testing to validate the safety profile of Elevidys.

Investors Business Daily

West Pharma Catapults, Making A Bullish Move, On Unexpectedly Strong Earnings

West Pharmaceutical stock catapulted Thursday after the medical player blew second-quarter expectations out of the water.

Investors Business Daily

Insmed Is Trading At A 25-Year High. Will Its 'Skeleton Key' Work?

Insmed stock is soaring as it approaches the potential approval of its second drug. CEO Will Lewis calls it a "skeleton key."

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock

Replimune stock cratered Tuesday after the Food and Drug Administration unexpectedly rejected its experimental melanoma treatment.

The Independent UK

Sarepta shares slide again as drugmaker bows to FDA pressure to pause gene therapy

Sarepta Therapeutics is pausing shipments of its gene therapy for muscular dystrophy following several patient deaths that have attracted attention from regulators

International Business Times

AstraZeneca To Invest $50 Bn In The US As Tariff Threat Looms

British pharmaceutical giant AstraZeneca said Tuesday it would invest $50 billion in the United States by 2030 amid Donald Trump's threats to impose tariffs on the sector.

Evening Standard

AstraZeneca pledges $50bn US investment ahead of drugs tariffs

Donald Trump is expected to announce tariffs of up to 200% on drugs makers in August

The Guardian - UK

AstraZeneca to invest $50bn in US by 2030 amid Trump tariff threats

UK company to fund new drug manufacturing facility in Virginia and expand R&D facilities around US

The Guardian - UK

Rachel Reeves vows to stick to fiscal rules and declines to rule out wealth tax – as it happened

Rolling coverage of the latest economic and financial news, as chancellor Rachel Reeves testifies to House of Lords economic affairs committee

The Independent UK

Major HRT supplier sanctioned after whistleblowers raise concerns over patient safety

A group of employees from Theramex, which supplies HRT treatments to millions of patients in the UK, wrote a letter to the pharmaceutical regulator

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.